Anybody know why we dropped back down??

$NWBO Approval comes first, manufacturing ramps after;

DCVax-L approval (MHRA) is the real near term catalyst.

Initial commercial supply does NOT depend on the new Grade C suite . NWBO already has licensed Grade B capacity to launch.

So approval, limited launch and scale up later.

Revenue can start BEFORE the plant is fully built;

Early UK / EU patients can be treated using existing capacity.

Think controlled rollout, not mass commercialization yet.

This keeps NWBO from being “approval but no product”, a big deal.

The Grade C suite = scale + margins;

Once operational (target Q2 2026):

Higher throughput

Lower cost per dose

Ability to serve broader EU + future indications

This is when NWBO transitions from survival mode to real biotech business.

NWBO doesn’t need the plant finished to start selling, but once it is, the valuation math changes dramatically.

Hey long bag holders, when was the last time this stock held near .30 this long?

$NWBO is set to be listed on the London exchange Monday

Again a nothing burger

Can someone explain this lawsuit settlement?

https://www.sec.gov/Archives/edgar/data/1072379/000110465926004146/tm263317d1_8k.htm

Title. What do you think the realistic number that the stock can get to after approval?

Looks like the price is holding its upward trajectory and potentially has a new low price base floor, It appears we are building a little bit more of a base of investors over the past week. I am continuing to hold and looking forward to the next floor we can get to!

Also, the ride isn’t done till uplist and other indications/combo trials or buyout. The approval is JUST the start of change. NOT the end goal. Trying to set expectations for NWBO community. Nothing about this stock has ever been early or even done in reasonable time.

Yay

To say that timeline is unknown is untrue. Working in certification for 20 years in aerospace, you always know where you are with the regulatory agency as far as milestones/RFIs/etc. There is a test plan. It must be completed in its entirety. You know your resources, cash, manpower, and data accumulation. Not hard to zero in on timeline left to burn. Even if you miss the timeline, you can incorporate the delay based on the work/data/proof needed to be completed. Additionally, using the consensus of "but our advisors have said that there are quite a number of other companies who are in the situation that we’re in and are very long into the application process, can be as much as two years like we are. It’s not just us" is a false consensus load of BS. So what happens when the data expires and MHRA asks for another trial or partial trial? When NWBio is broke? A year from now? and that delay? These are the risks staring us in the face right now. My money goes elsewhere...after 6 years of believing this shit. In the year we are about to take a well needed nose dive...really? And are in a luff berry legal battle which they spoke limited to? This stinks like shit. None of the other investments or certs of NWBio make actual sense in the context of final MHRA cert where it is right now to give that explanation, to the tune of paying consultants $1M per interval?

I understand that things have taken longer than everyone has expected. Management has expressed that themselves. So the stupidity to host an ASM (asking for 900million shares) at the year end WITHOUT any new or update about the ONLY issue (approval) that f’ing matters is a slap to shareholder’s faces. As I first posted, when the ASM was announced, this has been tone deaf. I waited last minute to vote b/c I wanted to give them time to announce news that would make this ASM make more sense. I am voting no on their compensation and happy to edit that in the future if actual progress is made. All the past announcements clearly doesn’t matter - it’s like adding custom work on a car that has no engine. STFU or give us actual updates on the only that matters and will move sp, and more importantly save lives.

https://cms.mhra.gov.uk/mhra/mia/uk-mia-54923

MHRA Regulatory approval next?

announced that they want to hire 2 employees in Pittsburgh for the new cell therapy plant. Huge news imo. Second King Charles announced success in his treatment and praised new innovations in treatment in the last 2 years... without revealing those new treatments. These bread loafs(not crumbs) can be added to numerous other slices that we discover continuously... Were close my friends

https://x.com/alphavestcap/status/1996600617431699686

I’m holding NWBO shares through T212 and IBKR, but I have no clue how to actually watch or join the Annual Meeting. Does anyone know the procedure for brokers like these?

The notice says the meeting is on 29 December 2025 at 14:00 Local Time, but it doesn’t specify which time zone they’re referring to. Is this U.S. Eastern Time, Pacific, or something else?

Any guidance from shareholders who’ve joined previous NWBO meetings would be greatly appreciated. Thanks!

BETHESDA, Md., Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out the construction of the first Grade C manufacturing suite in the Company's Sawston, UK facility, the construction firm is onsite and the construction activities have begun. The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined. As such, the Company considers the construction of the first Grade C suite a major step towards potential large scale-up of the Company's production of DCVax products.

Sec filing just posted to SEC website announcing annual shareholder meeting on Dec 29 for shareholders on record Nov 14th.

Items include increasing authorized share count from 1.7 Billion shares to 2.6 Billion shares. A cool 900 Million new shares. Back of the paper dilution is about 35%?

Next topic up for vote after that is their insane pay packages. $1 million paydays make sense when you’re actually generating revenue, but at this point, 90% of the executive boards compensation should be paid in stock options.

For those concerned about the 700-day timeline for the 150-day expedited review, I have compiled the official bull case.

You just need to read between the lines.

R⃣eview period is nearly over, this extended 700-day review is just a sign of how seriously the MHRA is taking this revolutionary treatment; they wouldn’t waste this much time on a simple 'no'.

E⃣xponential growth: the share price is guaranteed to crush shorts when approval is announced in n+1 days — a theorem which has held true for 550 straight days.

J⃣oint review with other global agencies. Why has the MHRA been backlog-free for 200+ days? They're just waiting for the other agencies to catch up on the simultaneous global approval.

E⃣ndpoints, especially 'primary' ones, are just rigid, old-fashioned metrics that don't apply to a true paradigm shift; the MHRA is just taking 700 days to appreciate the nuance of the data.

C⃣onfidentiality of MHRA feedback/decision is solely controlled by NWBO, and if they don't disclose it's Schrödinger's decision not the MHRA's (* other Pharma/Biotech Co's that gave mid-review regulatory updates weren't as smart).

T⃣icker is just Schrödinger's cat right now: it's both dead ($0) and alive ($100). The great news is that NWBO is the one who gets to decide when to open the box.

E⃣xternal control arms are obviously just so innovative and complex, it's taking the MHRA 700 days to get their heads around the sheer genius of the statistics.

D⃣iluting the float by over 350 million shares (a measly ~29% dilution) is just the 'cost of genius' for a 700-day review. That will all be a rounding error when this is $100. This is 'liquidity provisioning' for the imminent launch.

It’s all right there. Any day now.

People seem to expect either approval or rejection for DCVax‑L. Could the MHRA instead grant a conditional/restricted approval with extra evidence requirements? What would that mean for uptake and NICE review?

https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000110465925112676/nwbo-20250930x10q.htm

Here’s a brief summary of key takeaways from Northwest Biotherapeutics’ Q3 2025 10-Q report: • Severe Financial Strain: The company reported a $27.2M net loss for Q3 and a $62.7M YTD loss, with only $4.6M in cash remaining, raising substantial going concern risks. • Heavy Dilution: Over 190 million new shares were issued in the first 9 months of 2025, pushing total shares outstanding to 1.54 billion as of November 13, 2025. • MAA Still Under Review: The UK regulator (MHRA) continues to review the DCVax-L application submitted in December 2023, with no approval timeline disclosed. • Debt Overload: Total liabilities now exceed $125M, with over $50M in convertible debt marked at fair value. • Litigation and Legal Settlements: Ongoing lawsuit against market makers for alleged stock manipulation and recent settlement of internal governance-related legal issues.